Vaxcyte to Present at the Jefferies Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine company, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on June 9, 2022, at 8:30 a.m. ET. The event aims to highlight Vaxcyte's innovative approach to vaccine development, particularly its lead candidate, VAX-24, a broad-spectrum pneumococcal conjugate vaccine. A live webcast will be available on the company's website, with a replay accessible for 30 days post-conference.
- None.
- None.
SAN CARLOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 8:30 a.m. ET / 5:30 a.m. PT.
A live webcast of the presentation can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease and pneumonia. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.
Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com
Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com
FAQ
What is Vaxcyte's participation in the Jefferies Healthcare Conference?
What time is the Vaxcyte presentation at the conference?
How can I access the Vaxcyte conference presentation?
What is Vaxcyte's lead vaccine candidate?
What does Vaxcyte focus on in vaccine development?
